AGMB AgomAb Therapeutics (AGMB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002020932

Quote by TradingView

Cluster · 3 insidersC-suite buying · 2

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

What the filings say about AGMB

Insiders, 180 days

+$400.0K net bought

3 buyers

AgomAb Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AgomAb Therapeutics NV insiders bought a net $400.0K of stock across 10 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider

Filed

Value

Since filing

Epstein David R

Director

BUY

2026-10-22 SECtraded 2026-10-21

5,000

$44.3K

n/a

Context

3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 8, 2026.
The trade is 25.0% of the 20,000 shares held after it.
2 other insiders bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Director Epstein David R bought about $44.3K of AGMB on Oct 21, 2026; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.

Epstein David R

Director

BUY

2026-10-22 SECtraded 2026-10-21

5,000

$44.5K

n/a

Context

3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 8, 2026.
The trade is 20.0% of the 25,000 shares held after it.
2 other insiders bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Director Epstein David R bought about $44.5K of AGMB on Oct 21, 2026; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.

Epstein David R

Director

BUY

2026-10-09 SECtraded 2026-10-08

5,000

$44.5K

n/a

Context

2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Oct 6, 2026.
The trade is 33.3% of the 15,000 shares held after it.
2 other insiders bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Director Epstein David R bought about $44.5K of AGMB on Oct 8, 2026; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.

Knotnerus Tim Jasper

Chief Executive Officer

BUY

2026-10-07 SECtraded 2026-10-06

5,000

$43.5K

n/a

Context

1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 5, 2026.
The trade is 22.9% of the 21,823 shares held after it.
2 other insiders bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Chief Executive Officer Knotnerus Tim Jasper bought about $43.5K of AGMB on Oct 6, 2026; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.

Kemula Pierre Thadee Victor

Chief Financial Officer

BUY

2026-10-07 SECtraded 2026-10-06

3,000

$26.0K

n/a

Context

First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 100.0% of the 3,000 shares held after it.
2 other insiders bought within 30 days.
13 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Chief Financial Officer Kemula Pierre Thadee Victor bought about $26.0K of AGMB on Oct 6, 2026; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.

10 transactions on record

Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.

Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

net +$400.0K over 180 days

+$400.0K over 90 days

more than 84% of Pharma & Biotech

Congress

no House purchase disclosed in the last 12 months

Funds

13 funds bought in last quarter

below 77% of Pharma & Biotech

Revenue

no revenue reported in any filing

Margin

no margin: no revenue reported

Buybacks

no share repurchases reported

Short interest

5.4% of the float short (float per yahoo 2026-10-27) · 5.3 days to cover · settled 2026-10-15

below 61% of Pharma & Biotech

What changed in the last 30 days

Oct 22Director Epstein David R bought $219.7K (5 trades, Oct 5 to Oct 21)

Oct 7Chief Executive Officer Knotnerus Tim Jasper bought $94.4K (2 trades, Oct 5 to Oct 6)

Oct 7Chief Financial Officer Kemula Pierre Thadee Victor bought $85.9K (Oct 6)

Watch AGMB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns AGMB: institutional holders (13F)

13F holdings, latest reported quarter

EQT Fund Management S.a r.l.

5,141,992 sh

$66.7M

Nantahala Capital Management, LLC

3,136,376 sh

$40.7M

Sanofi

2,783,096 sh

$36.1M

Redmile Group, LLC

2,733,926 sh

$35.5M

Cormorant Asset Management, LP

2,465,348 sh

$32.0M

Congress trades in AGMB

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive

LSP 7 Cooperatieve U.A.

Activist 13D · 2026-02-17

10.6%

LSP 7 Management B.V.

Activist 13D · 2026-02-17

10.6%

AGMB planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

AGMB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).

Federated Hermes Kaufmann Small Cap Fund

$7.9M position · as of 2026-07-31

0.3%

Federated Hermes Kaufmann Fund

$12.6M position · as of 2026-07-31

0.3%

Federated Hermes Kaufmann Fund II

$274.0K position · as of 2026-06-30

0.2%

Steward Values Enhanced International Fund

$52.9K position · as of 2026-07-31

0.0%

Select Pharmaceuticals Portfolio

$102.4K position · as of 2026-05-31

0.0%

Blackstone Alternative Multi-Strategy Fund

$229.3K position · as of 2026-06-30

0.0%

SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

3 insiders reported buying shares.

The record shows a net $400.0K bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

UTHR CPIX MRNA REGN LLY ALNY MDGL CITR DNA VRTX NUVL TWST

AGMB Stock Sonar score 3/7 axes

Find similar shapes Compare

AGMB ranks highest on insider conviction (86th percentile) and risk and compliance (55th), and lowest on institutional and government (23rd), among Pharma & Biotech peers.

Insider conviction

Inputs

Net Form 4 buying (codes P and S), 180d$400K · 84 pct, sector of 428
Insider buyers, 180d3 · 89 pct, sector of 437

Institutional and government

Inputs

Funds adding, latest quarter13 · 23 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters

Risk and compliance

Inputs

Short interest, % of float+5.8% · 55 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)

4 not measured: Profitability, Financial health, Growth, US patents

Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AGMB filings, in plain words

Are AgomAb Therapeutics insiders buying or selling AGMB?

In the 180 days to 2026-10-28, AgomAb Therapeutics insiders were net buyers, a net $400.0K across purchases and sales reported on Form 4, by 3 buyers.

Read the full summary

In the 180 days to 2026-10-28, AgomAb Therapeutics insiders were net buyers of AGMB, a net $400.0K across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. The latest 5% ownership filing is a 13D by LSP 7 Cooperatieve U.A., filed 2026-02-17, for 10.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies